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ORIGINAL ARTICLE
In patients with community-acquired pneumonia
(CAP), prognosis prediction is important in order
to guide therapeutic options, such as the need
for ICU admission and choice of antibiotics.
Many studies have confirmed the effectiveness of
the pneumonia severity index (PSI) to predict
mortality. The Acute Physiology and Chronic
Health Evaluation (APACHE) II score is also a
widely accepted and validated severity scoring
system that assesses the risk of mortality for criti-
cally ill patients, such as those with severe CAP.
The APACHE II score has also been thought of 
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as an analogy of PSI to predict the outcome of 
severe CAP.1 In a recent study, the area under the
curve of APACHE II, used to estimate the mortality
of patients with ventilator-associated pneumonia,
was 0.81.2 Adding a parameter to increase the
value of predicting mortality is helpful to critical
care physicians.
Many biomarkers have been used to predict
the prognosis of CAP.3,4 Procalcitonin (PCT) has
been one of the more frequently checked bio-
markers in recent studies. However, although
PCT might be a reliable diagnostic marker that
can guide antibiotic use, it is not an ideal prog-
nostic tool.5 Also, soluble triggering receptor ex-
pressed on myeloid cells (sTREM)-1 is thought
to be a better marker than PCT and C-reactive
protein (CRP) to diagnose infection.6 Despite
this report, plasma sTREM-1 levels on day 1 can-
not be used to assess the treatment response of
patients with CAP.7 The anti-inflammatory cy-
tokines are a series of proteins that regulate the
inflammatory response. Interleukin (IL)-10, has
been reported as a parameter for predicting clini-
cal outcome of patients with severe CAP.8 IL-10 is
primarily synthesized by CD4+ type 2 T cells,
monocytes and B cells, and it may be the most im-
portant anti-inflammatory cytokine in the human
immune response.9 Another anti-inflammatory
cytokine, transforming growth factor (TGF)-β1,
suppresses the proliferation and differentiation
of T and B cells. TGF-β1 limits IL-2, interferon
(IFN)-γ, and tumor necrosis factor (TNF) 
production and acts as a monocyte/macrophage
deactivator.
However, as far as we are aware, no studies
have been conducted to evaluate the prognostic
predictive value of TGF-β1 in patients with severe
CAP. Therefore, we examined plasma IL-10 and
TGF-β1 levels in patients with severe CAP on the
day of admission to the emergency department.
We investigated whether plasma TGF-β1 level
served as a marker for predicting survival of pa-
tients with severe CAP, and if it was correlated
with disease severity. IL-6 is a well-studied prog-
nostic marker and was chosen as a reference cy-
tokine for comparison with other cytokines.
Methods
Subjects
From October 2003 to September 2005, patients
who were admitted to the emergency department
and soon transferred to the ICU at Chang Gung
Memorial Hospital because of severe CAP were
enrolled in this study, after the patient’s family
had provided informed consent. This study was
approved by the Institutional Review Board at
Chang Gung Memorial Hospital. The following
patient data were recorded at admission: age,
gender, medical history, and APACHE II score.
Comorbidities within the first 3 days were re-
corded. Standard treatment, including broad-
spectrum antibiotics, pleural effusion drainage if
needed, and basic support, was provided to all
patients. CAP was diagnosed on the basis of new
abnormal infiltration upon chest radiography,
with respiratory symptoms or fever. Severe CAP
was defined as that which necessitated ICU admis-
sion. Acute renal failure was diagnosed as a rap-
idly rising serum creatine level (> 0.5 mg/dL).10
Septic shock was defined as sepsis with hypoten-
sion that was unresponsive to fluid resuscitation,
according to criteria from the American College
of Chest Physicians/Society of Critical Care
Medicine Consensus Conference.11,12 Disease
severity was assessed with the APACHE II score.13
Mortality was defined as the 28-day mortality.
Cytokine measurement
Plasma samples on day 1 were obtained as soon as
possible upon admission to the emergency depart-
ment. All plasma samples were stored at −80°C
until used. Plasma levels of IFN-γ, IL-6, IL-10, IL-12
and TGF-β1 were measured utilizing human IFN-γ,
IL-6, IL-10 and IL-12 ELISA kits (Pierce Biotech-
nology, Rockford, IL, USA) and a TGF-β1 ELISA kit
(R&D Systems, Minneapolis, MN, USA), according
to the manufacturers’ instructions. Measurement
data were the average of the two readings.
Statistical analysis
Statistical analysis was performed using SPSS 
version 11.0.1 (SPSS Inc., Chicago, IL, USA) for
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Windows. Differences for continuous variables
(age, APACHE II score, cytokine level) between
survivors and non-survivors were analyzed with
the Mann–Whitney test. Differences for categorical
variables between survivors and non-survivors
were compared by the χ2 test or Fisher’s exact test.
The ability to distinguish survivors from non-
survivors in APACHE II score, IFN-γ, IL-6, IL-10,
IL-12 and TGF-β1 was tested by receiver operat-
ing characteristic (ROC) curves and areas under
the ROC curves (AUC). Logistic regression was used
to determine the independent factors in predicting
survival. Factors of APACHE II, septic shock, gas-
trointestinal bleeding, and plasma IL-6, IL-10 and
TGF-β1 levels were covariates. A value of p < 0.05
was considered statistically significant.
Results
Patient characteristics
Sixty-three patients were enrolled in this study.
Forty-nine patients were alive after 28 days and
14 died within 28 days. Table 1 shows the clini-
cal characteristics of survivors and non-survivors
with severe CAP. The mean APACHE II score of
non-survivors was significantly higher than that
of survivors. The percentage of septic shock and
gastrointestinal bleeding in non-survivors was
significantly higher than that in survivors.
Bacteriologic diagnosis
Pathogens were isolated from the sputum cul-
ture of 37 patients (58.7%). The pathogens fre-
quently identified were Klebsiella pneumoniae
(n = 9, 14.3%) and Pseudomonas aeruginosa (n = 8,
12.7%).
Cytokine levels upon admission and
predictive value
Table 2 and Figure 1 present the AUC and ROC
curves. The AUC of the APACHE II score and
plasma IL-6, IL-10 and TGF-β1 levels on day 1
was significantly different from 0.5. Conversely,
there was no significant difference in plasma
IFN-γ and IL-12 levels between the survivors and
Table 1. Demographic and clinical characteristics of patients with severe pneumonia*
Characteristics Survivors (n = 49) Non-survivors (n = 14)
Age (yr) 70.0 ± 2.0 69.1 ± 4.1
Gender
Male 32 (65.3) 8 (57.1)
Female 17 (34.7) 6 (42.9)
APACHE II score 22.7 ± 1.0 28.7 ± 2.3†
Chronic lung disease 13 (26.5) 5 (35.7)
Chronic renal disease 6 (12.2) 3 (21.4)
Diabetes mellitus 14 (28.6) 6 (42.9)
Heart failure 5 (10.2) 1 (7.1)
Old cerebrovascular accident 31 (63.3) 5 (35.7)
Hypertension 26 (53.1) 6 (42.9)
Organ failure
Septic shock 16 (32.7) 10 (71.4)‡
Bacteremia 6 (12.2) 2 (14.3)
Acute renal failure 25 (51.0) 9 (64.3)
Jaundice 8 (16.3) 1 (7.1)
Thrombocytopenia 20 (40.8) 5 (35.7)
Gastrointestinal bleeding 12 (24.5) 9 (64.3)‡
*Data presented as mean ± standard error or n (%); †p < 0.05 vs. survivors, Mann–Whitney Test; ‡p < 0.05 vs. survivors, χ2 test.
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non-survivors for mortality prediction. After lo-
gistical regression analysis, plasma TGF-β1 level
was the only independent factor associated with
mortality (Table 3), but the APACHE II score,
gastrointestinal bleeding, septic shock, IL-6 and
IL-10 were not. The cutoff value of APACHE II,
IL-6, IL-10 and TGF-β1 was chosen according to
the ROC curve, to obtain the best sensitivity and
specificity. The value of predicting mortality in
patients with severe CAP was similar for APACHE
II score, IL-6, IL-10, TGF-β1, septic shock and
gastrointestinal bleeding (Table 4).
Relationship of cytokine levels to 
APACHE II score
There was no difference in plasma IFN-γ and 
IL-12 levels between survivors and non-survivors,
therefore, plasma IFN-γ and IL-12 levels were not
analyzed to compare their relationship with
APACHE II score. Plasma IL-6 levels were not re-
lated to the APACHE II score (Figure 2). Plasma
IL-10 and TGF-β1 levels were related to the
APACHE II score (Figures 3 and 4). The correla-
tion coefficient (r) between plasma IL-10 level
and the APACHE II score was 0.384 (p = 0.002).
The r between plasma TGF-β1 level and the
APACHE II score was 0.27 (p = 0.032).
Discussion
This study is believed to be the first to report that
plasma TGF-β1 levels upon admission were 
Table 2. APACHE II scores and cytokine levels (pg/mL) on day 1 in survivors and non-survivors*†
95% CI of AUC
Survivors (n = 49) Non-survivors (n = 14) p‡ AUC
Lower Upper
APACHE II 22.73 ± 0.96 28.71 ± 2.31 0.012 0.722 0.553 0.892
IFN-γ 19.79 ± 18.70 3.20 ± 2.09 0.487 0.561 0.386 0.737
IL-6 90.16 ± 20.49 294.31 ± 79.18 0.015 0.714 0.538 0.891
IL-10 74.27 ± 15.32 277.34 ± 84.95 0.005 0.746 0.601 0.892
IL-12 28.19 ± 6.50 66.07 ± 23.19 0.215 0.609 0.418 0.801
TGF-β1 2276.62 ± 247.91 5699.77 ± 1586.44 0.002 0.778 0.658 0.899
*Data presented as mean ± standard error; †discrimination power is presented as AUC with 95% CI; ‡Mann–Whitney test. AUC = area under the receiver
operating characteristic curve; CI = confidence interval; APACHE = Acute Physiology and Chronic Health Evaluation; IFN = interferon; IL = interleukin; 
TGF = transforming growth factor.
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Figure 1. Receiver operating characteristic curves showed
that transforming growth factor (TGF)-β1, interleukin 
(IL)-10, IL-6 and Acute Physiology and Chronic Health
Evaluation (APACHE) II score on day 1 were good pre-
dictors for survival, while IL-12 and interferon (IFN)-γ
were not.
Table 3. Logistic regression to analyze independent factors for
predicting mortality
95% CI
p OR
Lower Upper
Gastrointestinal bleeding 0.062 5.531 0.919 33.276
Septic shock 0.532 1.916 0.250 14.704
APACHE II score 0.573 1.034 0.921 1.159
IL-6 0.918 1.000 0.994 1.006
IL-10 0.073 1.005 1.000 1.010
TGF-β1 0.037 1.000 1.000 1.001
OR = odds ratio; CI = confidence interval; APACHE = Acute Physiology and Chronic
Health Evaluation; IL = interleukin; TGF = transforming growth factor.
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different between survivors and non-survivors
with severe CAP. The value of predicting mortality
with plasma TGF-β1 levels was similar to that with
APACHE II scores. Septic shock is known to be a
predictor of mortality. In the present study, the
percentage of gastrointestinal bleeding in non-
survivors was significantly higher than that in
survivors. It is still unclear whether stress ulcer
bleeding is a predictor of mortality in patients
with severe CAP. This study showed that plasma
TGF-β1 level upon admission not only was a pa-
rameter to predict prognosis of CAP, but also an
independent factor that was not influenced by
clinical characteristics and plasma IL-6, IL-10 and
TGF-β1 levels. Plasma TGF-β1 levels were well
correlated with APACHE II scores. Although the
predictive value of clinical characteristics and cy-
tokine levels was similar, plasma TGF-β1 level
upon admission may potentially be an additional
parameter in a severity scoring system to increase
the accuracy of predicting mortality.
Anti-TGF-β antibodies can increase TNF-α
levels in cultured supernatant of bronchoalveolar
lavage cells and decrease the load of pulmonary
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Figure 3. Scatterplot of plasma interleukin (IL)-10 level
and Acute Physiology and Chronic Health Evaluation
(APACHE) II score on day 1 showed that IL-10 level is 
correlated with APACHE II score (r = 0.384, p = 0.002).
Table 4. Value of cytokines and clinical characteristics for predicting mortality in patients with severe pneumonia*
Parameter (cutoff value)
Reliability
APACHE II (25) IL-6 (48 pg/mL) IL-10 (42 pg/mL) TGF-β1 (2500 pg/mL) Shock GI bleeding
Sensitivity 71.4 71.4 71.4 71.4 71.4 64.3
Specificity 63.3 61.2 65.3 63.3 67.3 75.5
PPV 35.7 34.5 37.0 35.7 38.5 42.9
NPV 88.6 88.2 88.9 88.6 89.2 88.1
*Data presented as %. APACHE = Acute Physiology and Chronic Health Evaluation; IL = interleukin; TGF = transforming growth factor; GI = gastrointestinal;
PPV = positive predictive value; NPV = negative predictive value.
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Figure 2. Scatterplot of plasma interleukin (IL)-6 level and
Acute Physiology and Chronic Health Evaluation (APACHE)
II score on day 1 showed that IL-6 level is not correlated
with APACHE II score (r = 0.223, p = 0.079).
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Figure 4. Scatterplot of plasma transforming growth factor
(TGF)-β1 level and Acute Physiology and Chronic Health
Evaluation (APACHE) II score on day 1 showed that TGF-β1
level is correlated with APACHE II score (r = 0.27, p = 0.032).
pathogens in mice.14 Thus, we hypothesize that
TGF-β is a hindrance to controlling pneumonia.
Interestingly, Cui et al found that TGF-β1 treat-
ment is associated with a decrease in blood and
lung bacteria concentration in rats.15 Despite de-
creased blood and lung bacteria counts with
TGF-β1, overall survival rates are not significantly
altered with TGF-β1, whether administered once
or many times after bacterial challenge.15 One
possible reason why our results conflict with pre-
vious studies is that TGF-β has both pro- and
anti-inflammatory effects. Naïve CD4+ T cells
can develop into T helper 17 (Th17) cells in the
presence of IL-6 and TGF-β1, and regulatory T
(Treg) cells in the presence of TGF-β1.16 Th17
cells secrete IL-17, which acts in vitro and in vivo
as a potent inflammatory cytokine, and plays an
important role in acute lower respiratory tract in-
fection.17,18 Treg cells suppress T-cell function
both in vitro and in vivo, and depress the immune
response to the protective antigens in active tu-
berculosis.19,20 To sum up, TGF-β1 is important
in the pathogenesis of pneumonia and further
study is needed to elucidate its role.
The present study confirms that of Wu et al,
which showed that systemic IL-10 levels within 3
days of hospitalization could predict mortality in
patients with severe CAP.8 The AUC of IL-10 was
0.746, which was higher than that of the
APACHE II score (AUC = 0.722). Circulating IL-10
levels should be a good marker for predicting the
outcome of patients with severe CAP. Plasma IL-10
level in patients with severe CAP was associated
with APACHE II score. This result is the same as
that of Glynn et al, which showed that IL-10 level
was correlated with APACHE II score in patients
with CAP.21 In addition, IL-10 gene polymorphism
(–1082G/A) affects IL-10 expression and might
influence disease severity in patients with CAP.22
IL-10 plays a key role in severe CAP.
There was no difference in plasma IFN-γ and
IL-12 levels between survivors and non-survivors
with severe CAP in our study. IFN-γ has antiviral
activity, which augments TNF activity and induces
nitric oxide synthesis.23 Pinsky et al reported that
plasma IFN-γ levels in the first 48 hours after 
admission were not correlated with patient mor-
tality.24 Similarly, a study by Calandra et al
showed that survival duration is not correlated
with circulating IFN-γ level in patients with sep-
tic shock.25 Combining these findings indicates
that IFN-γ is involved in the pathogenesis of
CAP; however, the effect of IFN-γ on CAP is not
significant.
IFN-γ can enhance chemokine expression and
promote pulmonary neutrophil recruitment into
the infected lung. In mouse models, exogenous
IL-12 can improve the innate immune response
in the lung against Streptococcus pneumoniae, by
inducing IFN-γ production.26 However, the lack
of IL-12 in experimental Mycoplasma pneumoniae
pneumonia is associated with less severe pul-
monary disease and more rapid microbiologic
and histologic resolution.27 The results of this
conflict suggest that pneumonia has various im-
munopathogenic mechanisms, depending on
the different backgrounds of the host. Finally,
the absence of IFN-γ and IL-12 does not deny a
role for these cytokines in the pathogenesis of
pneumonia.
There are two limitations in the present study.
First, the timing of blood sampling may have in-
fluenced cytokine levels, especially after fluid re-
suscitation. However, as observation took place
during the standard treatment, investigators could
not delay the required resuscitation solely for
blood sampling. Despite this limitation, the dif-
ference in plasma IL-10 and TGF-β1 levels on ad-
mission between survivors and non-survivors with
severe CAP was very significant. Second, there
was a bias in patient inclusion under the present
medical knowledge. Healthcare-associated pneu-
monia was classified as CAP according to 2001
guidelines.28 However, the management of
healthcare-associated pneumonia has been dis-
cussed along with that of hospital-acquired and
ventilator-associated pneumonia after 2005.29
Patients with healthcare-associated pneumonia
may have been enrolled in this study at the ini-
tial period. This might explain the high percent-
age of K. pneumoniae and P. aeruginosa among the
isolated pathogens.
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In conclusion, plasma IL-6, IL-10 and TGF-β1
levels on admission were significantly different
between survivors and non-survivors with severe
CAP. Plasma TGF-β1 level on admission might
be a useful parameter to predict survival. A large-
scale study is needed to confirm this result and
obtain a more adequate cutoff value for the sen-
sitivity and specificity.
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